LLY vs WW
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. WW: A global weight management and wellness company transitioning its legacy subscription-based coaching and nutrition programs to a digital-first platform in an era of weight-loss pharmaceuticals.
Side-by-side fundamentals
| Metric | LLY | WW | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1,197.53 | $13.85 | |
| Market cap as of 2026-07-31 | $1.11T | $127M | |
| P/E as of 2026-07-31 | 43.84 | 0.12 | WW lower |
| PEG as of 2026-07-31 | 1.37 | n/a | |
| Net margin as of 2026-07-31 | +35.0% | +155.5% | WW higher |
| Gross margin as of 2026-07-31 | +82.8% | +72.0% | LLY higher |
| Operating margin as of 2026-07-31 | +43.6% | +166.5% | WW higher |
| ROE as of 2026-07-31 | +101.3% | +334.4% | WW higher |
| ROA as of 2026-07-31 | +22.7% | +112.5% | WW higher |
| Debt / equity as of 2026-07-31 | 1.39 | 1.75 | LLY lower |
| Revenue growth (YoY) as of 2026-07-31 | +47.4% | -9.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | -17.1% | LLY higher |
| Dividend yield as of 2026-07-31 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 0 | LLY higher |
| Beta as of 2026-07-31 | 0.51 | 1.20 | |
| 1-year return as of 2026-07-27 close | +47.4% | -66.2% | LLY higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.